Two new groundbreaking drugs could slow the memory impairment, thinking skills and overall brain decline — and both are ...

A new study identifies certain neurotoxins responsible for brain inflammation common to early on-set Alzheimer's disease and an oral medication that treats it.

Growing evidence suggests that the key to treating Alzheimer's is catching it in its earliest stages. Now scientists have ...

A promising Alzheimer's breakthrough as an experimental drug completely reverses mental decline in mice with advanced disease ...

After seeking care for escalating memory lapses, Diane Roussel received a devastating Alzheimer's diagnosis. She began ...

New research suggests Alzheimer’s may start far earlier than previously thought, driven by a hidden toxic protein in the brain. Scientists found that an experimental drug, NU-9, blocks this early ...

FDA grants priority review to Axsome's AXS-05 for treating agitation in Alzheimer's disease with a PDUFA date of April 30, 2026.

A new drug targets Alzheimer’s at its earliest, most silent stage — before memory loss ever begins. Credit: Shutterstock. A new experimental drug from ...

The biopharmaceutical company accepted for filing a supplemental new drug application for AXS-05 to treat Alzheimer's disease agitation, and has granted the application priority review designation, ...

The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association ...

Shanghai Fosun Pharmaceutical Group Co. will acquire a controlling stake in a Chinese company that developed the country’s ...

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...